Synthetic AIDS vaccine by targeting HIV receptor

Vaccine

Volumn 21, Issue 1-2, 2002, Pages 89-97

  Wang, Chang Yi ^a   Shen, Ming ^a   Tam, Gary ^b   Fang, Xin De ^a   Ye, John ^a   Shen, Fan ^a   Walfield, Alan M ^a   Wang, James J G ^a   Li, Ming Lie ^a   Li, Xuan Mao ^a   Salas, Maria ^b   Shearer, Michael H ^c   Kennedy, Ronald C ^c   Hanson, Carl V ^b  

^a United Biomedical Inc   (United States)

^b VIRAL AND RICKETTSIAL DISEASE LABORATORY   (United States)

^c UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

HIV; Receptor; Synthetic vaccine

Indexed keywords

CD4 ANTIGEN; EPITOPE; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MONOCLONAL ANTIBODY B4; POLYCLONAL ANTIBODY; PROTEIN 1403B; PROTEIN 1471C; PROTEIN 1684C; PROTEIN 1771B; PROTEIN 1817B; PROTEIN 1864X; PROTEIN 1889B; PROTEIN 1901B; PROTEIN 1990E; PROTEIN 1999E; PROTEIN 2028B; PROTEIN 2057C; PROTEIN P1471C; PROTEIN P1585C; PROTEIN P1586C; PROTEIN P1587C; PROTEIN P1588C; PROTEIN P1614C; PROTEIN P2189C; PROTEIN P2190C; PROTEIN P2240C; PROTEIN RSCD4; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRUS RECEPTOR; RECOMBINANT VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ACTIVE IMMUNIZATION; ANTIBODY RESPONSE; ARTICLE; B LYMPHOCYTE; BABOON; CELL SURFACE; CONTROLLED STUDY; HELPER CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; IMMUNOPROPHYLAXIS; IMMUNOTHERAPY; IMMUNOTOXICITY; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; ANIMAL; CHEMISTRY; GUINEA PIG; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; IN VITRO STUDY; ISOLATION AND PURIFICATION; METABOLISM; SERODIAGNOSIS; SWINE; SYNTHESIS; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION;

AIDS VACCINES; ANIMALS; ANTIGENS, CD4; EPITOPES; GUINEA PIGS; HIV ENVELOPE PROTEIN GP120; HIV-1; HUMANS; NEUTRALIZATION TESTS; SWINE; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES; VACCINES, SYNTHETIC;

EID: 0037159614     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(02)00432-2     Document Type: Article

References (39)

1. Rieber E.P., Reiter C., Gurtler L., Deinhardt F., Riethmuller G. Monoclonal CD4 antibodies after accidental HIV infection. Lancet. 336:1990;1007-1008.
2. Shearer M.H., Timanus D.K., Benton P.A., Lee D.R., Kennedy R.C. Cross-clade inhibition of human immunodeficiency virus type 1 primary isolates by monoclonal anti-CD4. J. Infect. Dis. 177:1998;1727-1729.
3. Trkola A., Dragic T., Arthos J.et al. CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. Nature. 384:1996;184-187.
4. Burkly L.C., Olson D., Shapiro R.et al. Inhibition of HIV infection by a novel CD4 domain 2-specific monoclonal antibody. Dissecting the basis for its inhibitory effect on HIV-induced cell fusion. J. Immunol. 149(5):1992;1779-1787.
5. Riemann K.A., Cate R.L., Wu Y.et al. In vivo administration of CD4-specific monoclonal antibody: effect on provirus load in rhesus monkeys chronically infected with the simian immunodeficiency virus of macaques. AIDS Res. Hum. Retroviruses. 11(4):1995;517-525.
6. Lopalco L., Barassi C., Pastori C.et al. CCR5-reactive antibodies in seronegative partners of HIV-seropositive individuals down-modulate surface CCR5 in vivo and neutralize the infectivity of R5 strains of HIV-1 in vitro. J. Immunol. 164(6):2000;3426-3433.
7. Lopalco L., Pastori C., Cosma A.et al. Anti-cell antibodies in exposed seronegative individuals with HIV type 1-neutralizing activity. AIDS Res. Hum. Retroviruses. 16(2):2000;109-115.
8. Wang C.Y., Sawyer L.S.W., Murthy K.K.et al. Post-exposure immunoprophylaxis of primary isolates by an antibody to HIV receptor complex. Proc. Nat. Acad. Sci. U.S.A. 96:1999;10367-10372.
9. Wang CY. Peptide composition for prevention and treatment of HIV infection and immune disorders. US Patent No. 6,090,388, 2000.
10. Moore ML. Peptide design consideration. In: Grant GA editor. Synthetic peptides: a users guide. New York: Freeman, 1992. Chapter 2, pp. 9-75.
11. Partidos C., Stanley C.M., Steward M.W. Immune responses in mice following immunization with chimeric synthetic peptides representing B and T cell epitopes of measles virus proteins. J. Gen. Virol. 72:1991;1293-1299.
12. Wahren B., Rosen J., Sandstrom E., Mathiesen T., Modrow S., Wigzell H. HIV-1 peptides induce a proliferative response in lymphocytes from infected persons. J. Acquir. Immun. Defic. Syndr. 4:1989;448-456.
13. Estaquier J., Gras-Masse H., Boutillon C.et al. The mixotope: a combinatorial peptide library as a T cell and B cell immunogen. Eur. J. Immunol. 24:1994;2789-2795.
14. Ladd AE, Wang CY, Zamb TJ. Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines. US Patent No. 5,759,551, 1998.
15. Wang C.Y., Chang T.Y., Walfield A.M.et al. Effective synthetic peptide vaccine for foot-and-mouth disease in swine. Vaccine. 20:2002;2603-2610.
16. Greenstein J.L., Schad V.C., Goodwin W.H.et al. A universal T cell epitope-containing peptide from hepatitis B surface antigen can enhance antibody specific for HIV gp120. J. Immunol. 148(12):1992;3970-3977.
17. Brett S.J., Mazurov A.V., Charles I.G., Tite J.P. The invasin protein of Yersinia spp. provides co-stimulatory activity to human T cells through interaction with b1 integrins. Eur. J. Immunol. 23:1993;1608-1614.
18. Stagg A.J., Elsley W.A.J., Pickett M.A., Ward M.E., Knight S.C. Primary human T-cell responses to the major outer membrane protein of Chlamydia trachomatis. Immunology. 79:1993;1-9.
19. Shen F., Chen P.D., Walfield A.M.et al. Differentiation of convalescent animals from those vaccinated against foot-and-mouth disease by a peptide ELISA. Vaccine. 17:1999;3039-3049.
20. Lang W., Anderson R.E., Perkins H.et al. Clinical, immunologic, and serologic finding in men at risk for acquired immunodeficiency syndrome. The San Francisco Men's Health Study. JAMA. 257(3):1987;326-330.
21. Shibata R., Hoggan M.D., Broscius C.et al. Isolation and characterization of a syncytium-inducing, macrophage/T-cell line-tropic human immunodeficiency virus type 1 that readily infects chimpanzee cells in vitro and in vivo. J. Virol. 69(7):1995;4453-4462.
22. Sawyer L.S.W., Wrin M.T., Crawford-Miksza L.et al. Neutralization sensitivity of human immunodeficiency virus type 1 is determined in part by the cell in which the virus is propagated. J. Virol. 68(3):1994;1342-1349.
23. Mascola J.R., Louder M.K., Surman S.R.et al. Human immunodeficiency virus type 1 neutralizing antibody serotyping using serum pools and an infectivity reduction assay. AIDS Res. Hum. Retroviruses. 12(14):1996;1319-1328.
24. Sattentau Q.J., Dalgleish A.G., Weiss R.A., Beverley P.C.L. Epitopes of the CD4 antigen and HIV infection. Science. 234:1986;1120-1123.
25. Jameson B.D., Rao P.E., Kong L.L.et al. Location and chemical synthesis of a binding site for HIV-1 on the CD4 protein. Science. 240:1988;1335-1339.
26. Wang J., Yan Y., Garrett T.P.J.et al. Atomic structure of a fragment of human CD4 containing two immunoglobulin-like domains. Nature. 348:1990;411-418.
27. Brady R.L., Dodson E.J., Dodson G.G. Crystal structure of domains 3 and 4 of rat CD4: relation to the NH2-terminal domains. Science. 260:1993;979-983.
28. Loetscher M., Geiser T., O'Reilly T., Zwahlen R., Baggiolini M., Moser B. Cloning of a human seven-transmembrane domain receptor, LESTR, that is highly expressed in leukocytes. J. Biol. Chem. 269(1):1994;232-237.
29. Samson M., Labbe O., Mollereau C., Vassart G., Parmentier M. Molecular cloning and functional expression of a new human CC-chemokine receptor gene. Biochemistry. 35(11):1996;3362-3367.
30. Littman D.R., Maddon P.J., Axel R. Corrected CD4 sequence. Cell. 55:1988;541.
31. Ladd AE, Wang CY, Zamb TJ. Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines. US Patent No. 5,843,446, 1998.
32. Walfield AM, Hosein B, Wang CY, Looney DJ, Wong-Staal F. High-titer neutralization of multiple HIV-1 isolates by radially branched immunogens. In: Koff WC, Wong-Staal F, Kennedy RC, editors. AIDS Research Reviews, vol. 3. New York: Marcel Dekker Inc., 1993. Chapter 18, pp. 345-60.
33. Wang C.Y., Looney D.J., Li M.L.et al. Long-term high-titer neutralizing activity induced by octameric synthetic HIV-1 antigen. Science. 254:1991;285-288.
34. Burton D.R., Pyati J., Koduri R.et al. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science. 266:1994;1024-1027.
35. Davis S.J., Schockmel G.A., Somoza C.et al. Antibody and HIV-1 gp120 recognition of CD4 undermines the concept of mimicry between antibodies and receptors. Nature. 358:1992;76-79.
36. Reimann K.A., Lin W., Bixler S.et al. A humanized form of a CD4-specific monoclonal antibody exhibits decreased antigenicity and prolonged plasma half-life in rhesus monkeys while retaining its unique biological and antiviral properties. AIDS Res. Hum. Retroviruses. 13(11):1997;933-943.
37. Kwang P.D., Wyatt R., Robinson J., Sweet R.W., Sodroski J., Hendrickson W.A. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Science. 393:1998;648-659.
38. Steward M.W., Stanley C.M., Obeid O.E.et al. A mimotope from a solid-phase library induces a measles virus-neutralizing and protective antibody response. J. Virol. 69(12):1995;7668-7673.
39. Chargelegue D., Obeid O.E., Shaw D.M.et al. Peptide mimics of conformationally constrained protective epitopes of respiratory syncytial virus fusion protein. Immunol. Lett. 57:1997;15-17.